CIDRAP: Study affirms fractional dosing with yellow fever vaccine
“According to a study … in the Annals of Internal Medicine, fractional dosing of the yellow fever vaccine offers recipients protective antibodies for up to 10 years without a booster dose. The results could inform the use of fractional dosing in preventive vaccination campaigns, and not just outbreak settings. … In related developments, the Nigeria Centre for Disease Control (NCDC) confirmed more cases in an ongoing outbreak in Edo state. … Nigeria is in the midst of the second phase of the largest yellow fever vaccination campaign ever, which aims to reach 26.2 million people to establish a high level of immunity in that country…” (Soucheray, 11/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.